healthpharma
Shares of Annovis Bio Inc (NYSE: ANVS) more than doubled on Tuesday after the biotech firm reported positive late-stage data for buntanetap. Buntanetap is the candidate treatment of ANVS for Parkinson’s disease. At the time of writing, Annovis stock is trading at $10.50 – still down some 45% versus the start of 2024. What does the data mean for Annovis stock?Buntanetap was shown to be effective in improving motor and nonmotor activities in a Phase 3 trial. It helped patients of Parkinson’s with overall cognitive function as well. Maria Maccecchini – the chief executive of Annovis Bio said in a...
Invezz
Eli Lilly & Co (NYSE: LLY) received approval for its Alzheimer’s drug from the Food & Drug Administration on Tuesday. The development is significant as it expands treatment options for the neurological disorder that affects close to 7 million Americans. At the time of writing, Eli Lilly shares are exchanging hands at $910. The pharma stock has gained more than 50% since the start of 2024. Is Kinsula news significant for Eli Lilly stock?Alzheimer’s is among the top five causes of deaths for Americans aged more than 65. More importantly, the number of patients suffering from this mind-wasting di...
Invezz
Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it matter for Humacyte stock?The Acellular Tissue Engineering Vessel of the company based out of North Carolina, United States caters to patients with advanced peripheral artery disease. ATEV is implantable and is used in vascular replacement and repair. Dr. Cindy Cao – the chief regulatory officer of Humacyte said in a press release today: We are exc...
Invezz
The probability of Donald Trump returning to the White House currently sits at about 60%, as per Andrew Lilley – the chief interest rate strategist at Barrenjoey. And if Joe Biden’s Republican rival does indeed win the 2024 U.S. elections, the following three health insurance stocks will likely benefit. Why may health insurance stocks benefit from Trump’s victory?The chances of Donald Trump securing a second term have increased about 5.0% since his debate with President Joe Biden on Thursday (June 27). If he does indeed return to office in November, Medicare Advantage stocks will rally, said B...
Invezz
CVS Health (NYSE: CVS) stock price is imploding as concerns about the pharmacy business continue. It has already plunged by more than 43% from its 2022 highs and is hovering at its lowest point since November 2020. Pharmacy woes are continuingThe pharmacy industry is not doing well as the biggest players in the industry face unprecedented competition and other challenges. Rite Aid, the third-biggest pharmacy chain in the US filed for bankruptcy amid rising debt levels and slow growth. On Thursday, Walgreen’s stock price fell apart as it crashed by over 30% after the company published weak resu...
Invezz
Shares of Walgreens Boots Alliance Inc. experienced a significant drop on Thursday following the release of its earnings report, plummeting to levels not seen since 1997. The company attributed the decline to persistent pressures on the US consumer and adverse marketplace dynamics that have negatively impacted pharmacy margins. Earnings report and store closures CEO Tim Wentworth highlighted the challenging operating environment, which has forced Walgreens to make substantial adjustments. As part of its strategic response, the company plans to close approximately 8,600 stores across the United...
Invezz
Walgreens Boots Alliance Inc (NASDAQ: WBA) trading down this morning after reporting weaker-than-expected financial results for its third quarter. Shares of the healthcare giant are now down close to 50% for the year. Walgreens stock sinks on disappointing guidanceWalgreens stock is in the red at writing also because its management lowered its guidance. The multinational now forecasts its adjusted per-share earnings to fall between $2.80 and $2.95 in fiscal 2024. Analysts, in comparison, were at $3.20 per share. Tim Wentworth – the chief executive of Walgreens Boots Alliance said in a press re...
Invezz
Novo Nordisk A/S (CPH: NOVO-B) climbed 3.0% to an all-time high on Tuesday after China approved the sale of its weight-loss treatment Wegovy. Year-to-date, shares of the pharmaceutical giant are now up a whopping 45%. Why is it a big deal for Novo Nordisk stock?Novo Nordisk is yet to reveal the details of its launch plan. How much will its weight-loss drug cost in China remains unknown as well. Nonetheless, the announcement is significant for Novo Nordisk stock as it clears the path for Wegovy to generate sales from the world’s second largest economy. Initially, the weekly injectable will be a...
Invezz
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company are now trading at a year-to-date high of $220. Why is it significant for Alnylam Pharmaceuticals stock?Vutrisiran demonstrated significant efficacy in reducing mortality and cardiovascular complications in the aforementioned study. It’s a drug that targets transthyretin amyloidosis with cardiomyopathy – a condition that stiffens the heart and impairs blood pumping. Pushkal Garg – the chief medical offi...
Invezz
Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing. Alimera Sciences stock valued at a 75% premiumANI Pharmaceuticals is willing to pay $5.50 in cash for each share of Alimera Sciences. It has also agreed to 50 cents a share of additional payout provided that the acquiree hits certain revenue targets in 2026 and 2027. Nikhil Lalwani – the chief executive of $ANIP said in a press release on Monday: We believ...
Invezz
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら